title: Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
abstract: OBJECTIVE
  To explore patient and disease factors, and reasons behind the physician's choice of platinum backbone for the first-line treatment of non-small cell lung cancer (NSCLC), as observed in a European prospective observational study of patients receiving platinum-based chemotherapy as first-line treatment for advanced or metastatic NSCLC (the FRAME study). Additionally, overall survival (OS) for patients who received cisplatin or carboplatin was evaluated.
  
  
  METHODS
  A post-hoc analysis of the prospective study population was conducted. Baseline characteristics of patients receiving cisplatin versus carboplatin were compared and summarized by propensity score. Survival for matched patients was summarized using the Kaplan-Meier approach.
  
  
  RESULTS
  Of the 1564 patients who were included in the prospective study, 1520 received either cisplatin (54%) or carboplatin (46%) in combination with pemetrexed, gemcitabine, taxanes or vinorelbine. Patients treated with carboplatin were older than patients receiving cisplatin (mean age 67 versus 61 years; p<0.001), had poorer performance status (p<0.001), and more comorbidities (p<0.001). Cisplatin was most frequently combined with pemetrexed (47%), and carboplatin most frequently with taxanes (31%). Unadjusted median OS estimates for patients from the total prospective study sample were 11.5 months (95% confidence interval [CI] 10.1-12.9) for cisplatin recipients and 9.0 months (95% CI 8.1-10.6) for carboplatin recipients. Median (95% CI) overall survival for the matched cohorts was 10.8 months (8.8-14.3) for cisplatin versus 9.5 months (8.2-11.3) for carboplatin; p=0.086.
  
  
  CONCLUSIONS
  This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients.
authors.affiliation: Vrije Universiteit Medical Centre, Amsterdam, The Netherlands. Electronic address: EF.smit@vumc.nl.
authors.forename: Egbert
authors.initials: E
authors.lastname: Smit
authors.affiliation: Unité d'Oncologie Thoracique-Pneumologie, CHU de Grenoble, INSERM U823, Grenoble, France.
authors.forename: Denis
authors.initials: D
authors.lastname: Moro-Sibilot
authors.affiliation: Hospital Universitario La Paz, Madrid, Spain.
authors.forename: Javier de Castro
authors.initials: Jde C
authors.lastname: Carpeño
authors.affiliation: Medical University of Gdańsk, Gdynia, Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Lesniewski-Kmak
authors.affiliation: Amphia Hospital Breda, Rotterdam, The Netherlands; Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Joachim
authors.initials: J
authors.lastname: Aerts
authors.affiliation: Hospital Costa del Sol, Marbella, Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Villatoro
authors.affiliation: Eli Lilly and Company, Houten, The Netherlands.
authors.forename: Kees
authors.initials: K
authors.lastname: Kraaij
authors.affiliation: Eli Lilly and Company, Neuilly-sur-Seine, France.
authors.forename: Karim
authors.initials: K
authors.lastname: Nacerddine
authors.affiliation: Eli Lilly GmbH, Vienna, Austria.
authors.forename: Yulia
authors.initials: Y
authors.lastname: Dyachkova
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Karen T
authors.initials: KT
authors.lastname: Smith
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Allicia
authors.initials: A
authors.lastname: Girvan
authors.affiliation: Eli Lilly and Company, Houten, The Netherlands.
authors.forename: Carla
authors.initials: C
authors.lastname: Visseren-Grul
authors.affiliation: Institut für Allgemeine und Spezielle Pathologie, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.
authors.forename: Philipp A
authors.initials: PA
authors.lastname: Schnabel
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005060:Europe; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D057216:Propensity Score; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D002945:Cisplatin
keywords: Carboplatin; Cisplatin; Non-small cell lung cancer; Observational study